# Louis Fehrenbacher

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/louis-fehrenbacher/

## Facts

| Field | Value |
| --- | --- |
| Citations | 59,146 |
| Field | Breast Cancer Treatment Studies |
| h-index | 79 |
| i10-index | 140 |
| Last Known Institution | Kaiser Permanente |
| OpenAlex ID | https://openalex.org/A5074479466 |
| ORCID iD | https://orcid.org/0000-0002-1300-1905 |
| Works | 216 |

## Researcher papers

- [Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-plus-adjuvant-chemotherapy-for-operable-her2-positive-breast-cancer/)
- [Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-for-patients-with-previously-treated-non-small/)
- [Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation](https://scholariq.org/papers/talazoparib-in-patients-with-advanced-breast-cancer-and-a-germline-i-brca-i/)
- [Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer](https://scholariq.org/papers/randomized-phase-iii-trial-of-capecitabine-compared-with-bevacizumab-plus/)
- [Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer/)
- [Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer](https://scholariq.org/papers/early-discontinuation-and-non-adherence-to-adjuvant-hormonal-therapy-are/)
- [Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients](https://scholariq.org/papers/early-discontinuation-and-nonadherence-to-adjuvant-hormonal-therapy-in-a-cohort/)
- [Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme](https://scholariq.org/papers/phase-ii-study-of-bevacizumab-plus-temozolomide-during-and-after-radiation/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)

## Researcher university

- [Kaiser Permanente](https://scholariq.org/institutions/kaiser-permanente/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.